Blog

David Gandara: Jonathan Riess about impact of baseline positive vs negative plasma ctDNA

Photo collage of Jonathan Riess and David Gandara

Aug 27, 2024, 21:52

David Gandara: Jonathan Riess about impact of baseline positive vs negative plasma ctDNA

David Gandara, Co-Director-Center for Experimental Therapeutics at UC Davis Comprehensive Cancer Center, shared a post on X:

“At Cal Cancer Consortium conference, Jonathan Riess shows impact of baseline positive vs negative plasma ctDNA for EGFR in the FLAURA2 trial. Addition of chemo to Osi mainly benefitting those with positive ctDNA. Food for thought!”

Source: David Gandara/X

Cal Cancer Consortium cancer Cancer research chemotherapy ctDNA Impact David Gandara EGFR Experimental Therapeutics FLAURA2 Trial Jonathan Riess OncoDaily Oncology Oncology Conference osimertinib plasma ctDNA UC Davis Comprehensive Cancer Center

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage